Reducing time from gene to IND is an important consideration in developing new processes and decreasing the cost for customers. Through the use of GS piggyBac® transposon technology, a substantial improvement can be achieved by pseudo-targeting DNA cargos to integration sites where expression of recombinant proteins are likely to be higher in a wide variety of cell types. When used in combination with the Beacon® Optofluidics system, additional resource and time savings can be achieved.
You may also be interested in:
View our poster
Latest briefing from the Knowledge Center
Jet Milling: A Key Process for Manufacturing Inhaled Particles
Carrier-based formulations for dry powder inhalers are precisely designed to transport extremely...
Unveiling Consumer Preferences for Oral Solid Dosage Forms. Capsules in the Spotlight
The article "Unveiling Consumer Preferences for Oral Solid Dosage Forms. Capsules in the Spotlight"...
Straight to Market in an Autoinjector
A smart, data-driven approach to formulate biotherapeutics for PFS with confidence The global...
GS Effex® Cell Line for Enhanced Antibody Effector Function
GS Effex® derived from Lonza's leading GS Xceed® cell line, has been engineered to lack the enzyme...
GS Xceed® Gene Expression System Brochure
GS Xceed® is a scalable, integrated, proven platform for developing biotherapeutics. The system is...
Early Solid Form Screening: A Case Study
Solid form screening is highly customizable based on the phase of the drug development life cycle,...
Accelerating Small Molecule Advancements
The increasing number of breakthroughs in small molecule drug development are exciting, but...
Cis-targeted Immunotherapies Need Large CDMO Expertise but also Flexibility
Asher Biotherapeutics is developing a pipeline of cis-targeted immunotherapies that selectively...
Transparent Communication Supports Tech Transfers of Cis-targeted Immunotherapies
Asher Biotherapeutics embarked on a search for a contract development and manufacturing organization...
Accelerate your ADC Journey: Filling the Need for Integrated Bioconjugate Solutions
Lonza is further reshaping the ADC landscape by introducing new Drug Product capabilities that...
Rapid and Material-Sparing Feasibility Screening for Hot Melt Extrusion
Amorphous solid dispersions (ASD) offer a bioavailability enhancement drug delivery solution for...